The sales of medicines for obstructive airway diseases in Sweden stood at 247 million US Dollars PPP in 2023. Forecasts for 2024 to 2028 show a steady growth in sales, with values projected to rise from 248.5 million US Dollars PPP in 2024 to 253.8 million US Dollars PPP by 2028. Year-on-year growth percentages indicate incremental increases: 0.6% in 2025, 0.56% in 2026, 0.52% in 2027, and 0.43% in 2028. The compound annual growth rate (CAGR) over the five-year period is approximately 0.46%.
Future trends to watch in this market include advancements in treatment options and new drug approvals, which may accelerate sales growth. Additionally, demographic changes such as an aging population and increasing prevalence of respiratory diseases could further drive the market. Keeping an eye on healthcare policy changes and reimbursement scenarios in Sweden will also be crucial, as they could impact market dynamics.
